Endo Oxymorphone Immediate-Release Study Cleared By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency grants final approval to short-term, repeat-dose study of oxymorphone IR. FDA asks Endo to clarify aspects of its outcomes analysis for a new trial of an extended-release formulation prior to final approval of study protocol.
You may also be interested in...
Endo Oxymorphone ER Protocol Approved
Endo expects to submit a complete response to FDA's "approvable" letter for its extended-release oxymorphone "in early 2006.
Endo Oxymorphone ER Protocol Approved
Endo expects to submit a complete response to FDA's "approvable" letter for its extended-release oxymorphone "in early 2006.
Endo Oxymorphone ER Response To FDA “Approvable” Letter Expected In 2005
The firm will submit a new study, designed under FDA’s special protocol assessment procedures, in 250-300 opioid-naïve patients with chronic low back pain. Bias concerns raised about dropouts in other trials will be addressed through titration.